BioMimetic claims FDA first for periodontal regeneration product
This article was originally published in Clinica
Executive Summary
Making its market debut, BioMimetic Therapeutics has received US approval for what it claims is the first recombinant growth factor to be sanctioned by the FDA for use in periodontal applications.